Form 6-K BioNTech SE For: Nov 05

Go back to Form 6-K BioNTech SE For: Nov 05

BioNTech (BNTX) PT Lowered to $289 at Goldman Sachs

November 11, 2021 7:19 AM EST

Goldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $289.00 (from $433.00) while maintaining a Neutral rating.

The analyst commented, "While vaccine marketplace trends continue to provide tailwinds for mRNA-vaccine manufacturers, more hesitant management commentary around the endemic phase... More